Lexaria Bioscience Corp.’s disruptive patented technology DehydraTECH™ is available to be licensed by the drug and pharmaceutical industry.

DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of product formats including:

• Registered Drugs
• Nutraceuticals
• Capsules, Pills and Tablets
• Oral Suspensions
• Topical Applications

DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system. The technology has demonstrated affinity for transdermal applications and demonstrated effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has a proven track record of, and is actively conducting in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of APIs through ingestible means. Test data consistently shows that DehydraTECH reduces the time required to enter the bloodstream, increases absorption rate, and also improves the taste and smell of edible products.

For more information on study results, visit our Research page